Gilead, Teva Defeat $3.6B HIV Drug Antitrust Case At Trial
A California federal jury cleared Gilead and Teva on Friday in a $3.6 billion antitrust case claiming the pharmaceutical giants struck an illegal "pay-for-delay" patent deal that inflated prices for two HIV...To view the full article, register now.
Already a subscriber? Click here to view full article